Tao Synergies Inc (TAOX)

$4.40 -0.20 (-4.35%)
Market Cap 32.79M
Revenue (ttm) 0.00
Net Income (ttm) -12.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 77,226
Avg Vol 346,136
Day's Range N/A - N/A
Shares Out 7.13M
Stochastic %K 2%
Beta 1.94
Analysts Strong Buy
Price Target N/A

Company Profile

TAO Synergies Inc. owns and operates an AI token. The company executes a cryptocurrency treasury strategy centered on the acquisition and staking of the TAO token, the native utility token of the Bittensor network. TAO Synergies Inc. was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025. The company was incorporated in 2012 and is headquartered in New York, New York.

Industry: Software - Infrastructure
Sector: Technology
Phone: 973 242 0005
Address:
1185 Avenue of the Americas, 3rd Floor, New York, United States
DAppDeveloper
DAppDeveloper Dec. 26 at 9:40 AM
$TAOX Market expectations are recalibrating toward measurable delivery and away from assumptions. Execution gaps should narrow meaningfully. Missed steps could quickly reignite skepticism. The outlook strengthens only as evidence accumulates.
0 · Reply
PagodaPips
PagodaPips Dec. 25 at 11:58 AM
$TAOX Capital stewardship is becoming the defining attribute for how this story is priced. The market is increasingly intolerant of delays that stretch credibility. Strategic clarity can reduce risk premiums even before growth accelerates. Overall, the trajectory is less about vision and more about proving the operating model works.
0 · Reply
TaoistTrader
TaoistTrader Dec. 24 at 5:59 PM
$TAOX this seems to lag behind Tao a bit, which is recovering today. The halving appears to have triggered a sell the news , and the stock could also be suffering from tax write offs. Will look for recovery in early 2026
0 · Reply
green_going_up
green_going_up Dec. 24 at 5:32 PM
$TWAV $TAOX $TAO.X Bittensor double-topped in Dec 2024 and saw a ton of volatility in 2025. Alt coins have been taken out to the woodshed and destroyed, yet Bittensor has seen strong growth in subnets as it builds through a difficult macro environment. With 129 subnets and growing, its Fully-Diluted Market Cap of $5 Billion will likely prove to be extraordinarily cheap when one looks back a few years from now.
0 · Reply
EndGame1
EndGame1 Dec. 23 at 3:22 AM
$TAOX Didn’t expect this. Will just wait for crypto to recover.
1 · Reply
mightx
mightx Dec. 15 at 6:43 PM
$TAOX added
0 · Reply
EndGame1
EndGame1 Dec. 12 at 2:52 PM
$TAOX Back to the 20 daily moving average. Now onward to the 50DMA of $7.50.
0 · Reply
Mar_3
Mar_3 Dec. 10 at 11:25 PM
$JPM $MSFT $QCLS $TAO.X $TAOX
0 · Reply
green_going_up
green_going_up Dec. 10 at 10:59 PM
$QCLS It's NOT where a firm has been, it's where a firm is going. The FACT is LightSolver is one of the brightest (no pun intended) privately held firms. QCLS has an Exclusive License of the LightSolver Photonic Computing tech for Blockchains. $JPM's Dimon said this week how Blockchains are increasingly being used by the bank across end-markets. $MSFT has shown their work in Photonic Computing - similar to that of LightSolver's - can function as a Quantum Computing Alternative at a potentially much better ROI. Read the Microsoft Research on this! I'm not a fan of Martin's, but I respect that he is savvy, and he has has served the jail time. Meanwhile James is running $TAOX which owns a lot of $TAO.X - the #1 de-centralized AI firm in the crypto space (i.e. the de-centralized ledge space, i.e. the Blockchain space). TAO has two subnets in Quantum Computing and James can help create subnets that use LightSolver tech licensed by QCLS. Understand the vision before commenting!
0 · Reply
TaoistTrader
TaoistTrader Dec. 10 at 9:02 PM
$TAO.X tick tock tick tock $TAOX
1 · Reply
Latest News on TAOX
Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

Nov 18, 2025, 5:15 PM EST - 5 weeks ago

Options Trading Now Available on Tradr's BEX, CSEX, NNEX & SNPXcsex

BEX CSEX NNEX SNPX

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Nov 18, 2025, 9:15 AM EST - 5 weeks ago

TAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI Innovation

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

Nov 13, 2025, 1:37 PM EST - 6 weeks ago

Tradr Expands Leveraged Lineup With 4 New Single-Stock ETFs Targeting AI Infrastructure Firms

BEX CSEX NNEX SNPX

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

Nov 13, 2025, 6:46 AM EST - 6 weeks ago

Tradr Launches Leveraged ETFs on Bloom Energy, Celestica, NANO Nuclear & Synopsys

BEX CSEX NNEX SNPX

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

Nov 11, 2025, 11:26 AM EST - 6 weeks ago

Tradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and Synopsys

BEX CSEX NNEX SNPX

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

Nov 4, 2025, 9:15 AM EST - 7 weeks ago

TAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet Funds

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

Oct 20, 2025, 9:15 AM EDT - 2 months ago

TAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI Cryptocurrency

TAO Synergies Announces $11 Million Private Placement

Oct 13, 2025, 5:09 PM EDT - 2 months ago

TAO Synergies Announces $11 Million Private Placement

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

Sep 22, 2025, 9:15 AM EDT - 3 months ago

TAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

Sep 8, 2025, 9:15 AM EDT - 3 months ago

TAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI Event

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

Aug 26, 2025, 9:15 AM EDT - 4 months ago

TAO Synergies Welcomes Top Bittensor (TAO) Leader as Advisor for AI-Focused Crypto Treasury Strategy

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Jul 1, 2025, 9:15 AM EDT - 6 months ago

TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Jun 26, 2025, 9:15 AM EDT - 6 months ago

Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Jun 24, 2025, 9:15 AM EDT - 6 months ago

Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Jun 9, 2025, 9:00 AM EDT - 7 months ago

Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Dec 20, 2024, 9:15 AM EST - 1 year ago

Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength

Synaptogenix Announces $5.0 Million Financing

Sep 11, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces $5.0 Million Financing

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Jul 18, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Jun 26, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Announces FDA Authorization of IND Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

May 7, 2024, 9:00 AM EDT - 1 year ago

Synaptogenix Applauds DEA Proposal to Reclassify Cannabis and Shares Expected Benefits to Cannasoul for Cannabinoid-Based Drug Discovery

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Apr 24, 2024, 9:15 AM EDT - 1 year ago

Synaptogenix Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Apr 3, 2024, 8:00 AM EDT - 1 year ago

Synaptogenix Announces Reverse Stock Split to Maintain Nasdaq Listing

Synaptogenix President Daniel L. Alkon, M.D.

Dec 19, 2023, 9:00 AM EST - 2 years ago

Synaptogenix President Daniel L. Alkon, M.D.

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Dec 6, 2023, 9:00 AM EST - 2 years ago

Synaptogenix Joins Leading Neuroscientists and Academics as Speaker at USC-Sponsored Forum on Age-Related Diseases including Alzheimer's

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Nov 2, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The Technion - Israel Institute of Technology

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Sep 26, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Announces Peer-Reviewed Publication of NIH-Sponsored Phase 2 Clinical Trial Results Demonstrating Safe, Significant, and Persistent Benefits of Bryostatin-1 in Advanced Alzheimer's Disease

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Sep 7, 2023, 9:00 AM EDT - 2 years ago

Bryostatin-1 from Synaptogenix Shows Statistically Significant Results as an ALS Treatment in Pre-Clinical Independent Study

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Jul 19, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix and Cleveland Clinic to Submit Investigational New Drug (IND) Application to FDA for Clinical Trial of Bryostatin-1 in Multiple Sclerosis

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Jul 13, 2023, 9:00 AM EDT - 2 years ago

Synaptogenix Abstract Highlighting Bryostatin-1 Benefits in Severe Alzheimer's Disease Accepted for Presentation at 11th International Brain Research Organization World Congress of Neuroscience

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

Mar 7, 2023, 9:00 AM EST - 3 years ago

Synaptogenix Provides Corporate Update and Outlines Potential Business Opportunities

5 Health Care Stocks That Are Diving - And May Rally

Jan 19, 2023, 8:58 AM EST - 3 years ago

5 Health Care Stocks That Are Diving - And May Rally

FATE IPSC TECH

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Dec 16, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces Topline Results from NIH-Sponsored Phase 2 Clinical Trial of Bryostatin-1 for Advanced Alzheimer's Disease

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Dec 9, 2022, 11:50 AM EST - 3 years ago

Synaptogenix: Bryostatin For Alzheimer's, As Binary As Can Be

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Nov 18, 2022, 9:00 AM EST - 3 years ago

Synaptogenix Announces $15 Million Private Placement with Existing Investors

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Oct 19, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix to Present at ThinkEquity Investor Conference on October 26, 2022

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Sep 28, 2022, 11:50 AM EDT - 3 years ago

Synaptogenix Welcomes Lecanemab Phase 3 Trial Results

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Aug 12, 2022, 9:00 AM EDT - 3 years ago

Synaptogenix Announces Live Appearance of its President and CSO on Streaming Financial News Network

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Jul 26, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Changes to Scientific Advisory Board in Preparation for Phase 2 Data

Synaptogenix Announces Corporate Update Conference Call

Jul 21, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Announces Corporate Update Conference Call

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Jul 20, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix Advances Dosing of First Patient in Dose Optimization Clinical Trial in Preparation for NIH-Sponsored, Phase 2 Alzheimer's Disease Trial Data

Synaptogenix to Present at the Cell Symposium

May 17, 2022, 9:15 AM EDT - 3 years ago

Synaptogenix to Present at the Cell Symposium

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

Apr 19, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix Completes Patient Enrollment in NIH Sponsored Phase 2b Alzheimer's Disease Trial

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Apr 5, 2022, 9:15 AM EDT - 4 years ago

New Peer Reviewed Article Demonstrates Extended Therapeutic Potential of Synaptogenix's Bryostatin for Alzheimer's Disease

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Mar 29, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Hanson Wade 10th Annual Neurodegenerative Drug Development Summit

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Mar 22, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present at Sachs 5th Annual Neuroscience Innovation Forum

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Mar 15, 2022, 9:15 AM EDT - 4 years ago

Synaptogenix to Present Research Highlighting Potential Broad Applicability for Lead Compound Bryostatin at the International Conference on Alzheimer's and Parkinson's Diseases (AD/PD 2022)

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Feb 23, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Feb 1, 2022, 9:15 AM EST - 4 years ago

Synaptogenix Announces Publication of Peer-Reviewed Scientific Article Evidencing Byrostatin-1's Improved Cognition Over Baseline in Advanced Alzheimer's Disease Patients

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

Nov 16, 2021, 11:07 PM EST - 4 years ago

Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

Nov 15, 2021, 9:28 AM EST - 4 years ago

5 Short Squeeze Candidates To Watch: Huadi Tops List, Altimeter Group And Bit Digital Rejoin Leaderboard

BTBT HUDI

DAppDeveloper
DAppDeveloper Dec. 26 at 9:40 AM
$TAOX Market expectations are recalibrating toward measurable delivery and away from assumptions. Execution gaps should narrow meaningfully. Missed steps could quickly reignite skepticism. The outlook strengthens only as evidence accumulates.
0 · Reply
PagodaPips
PagodaPips Dec. 25 at 11:58 AM
$TAOX Capital stewardship is becoming the defining attribute for how this story is priced. The market is increasingly intolerant of delays that stretch credibility. Strategic clarity can reduce risk premiums even before growth accelerates. Overall, the trajectory is less about vision and more about proving the operating model works.
0 · Reply
TaoistTrader
TaoistTrader Dec. 24 at 5:59 PM
$TAOX this seems to lag behind Tao a bit, which is recovering today. The halving appears to have triggered a sell the news , and the stock could also be suffering from tax write offs. Will look for recovery in early 2026
0 · Reply
green_going_up
green_going_up Dec. 24 at 5:32 PM
$TWAV $TAOX $TAO.X Bittensor double-topped in Dec 2024 and saw a ton of volatility in 2025. Alt coins have been taken out to the woodshed and destroyed, yet Bittensor has seen strong growth in subnets as it builds through a difficult macro environment. With 129 subnets and growing, its Fully-Diluted Market Cap of $5 Billion will likely prove to be extraordinarily cheap when one looks back a few years from now.
0 · Reply
EndGame1
EndGame1 Dec. 23 at 3:22 AM
$TAOX Didn’t expect this. Will just wait for crypto to recover.
1 · Reply
mightx
mightx Dec. 15 at 6:43 PM
$TAOX added
0 · Reply
EndGame1
EndGame1 Dec. 12 at 2:52 PM
$TAOX Back to the 20 daily moving average. Now onward to the 50DMA of $7.50.
0 · Reply
Mar_3
Mar_3 Dec. 10 at 11:25 PM
$JPM $MSFT $QCLS $TAO.X $TAOX
0 · Reply
green_going_up
green_going_up Dec. 10 at 10:59 PM
$QCLS It's NOT where a firm has been, it's where a firm is going. The FACT is LightSolver is one of the brightest (no pun intended) privately held firms. QCLS has an Exclusive License of the LightSolver Photonic Computing tech for Blockchains. $JPM's Dimon said this week how Blockchains are increasingly being used by the bank across end-markets. $MSFT has shown their work in Photonic Computing - similar to that of LightSolver's - can function as a Quantum Computing Alternative at a potentially much better ROI. Read the Microsoft Research on this! I'm not a fan of Martin's, but I respect that he is savvy, and he has has served the jail time. Meanwhile James is running $TAOX which owns a lot of $TAO.X - the #1 de-centralized AI firm in the crypto space (i.e. the de-centralized ledge space, i.e. the Blockchain space). TAO has two subnets in Quantum Computing and James can help create subnets that use LightSolver tech licensed by QCLS. Understand the vision before commenting!
0 · Reply
TaoistTrader
TaoistTrader Dec. 10 at 9:02 PM
$TAO.X tick tock tick tock $TAOX
1 · Reply
TaoistTrader
TaoistTrader Dec. 9 at 4:14 PM
$TAO.X $TAOX
0 · Reply
EndGame1
EndGame1 Dec. 9 at 3:51 PM
$ASST $TAOX $DGXX $BLNE $DVLT My young Thoroughbreds.
0 · Reply
EndGame1
EndGame1 Dec. 6 at 4:44 AM
$TAOX It was another fake out. Just like $ASST TAOX isn't going up big until $BTC.X does.
0 · Reply
EndGame1
EndGame1 Dec. 4 at 1:43 PM
$TAOX Looks to me like TAO coin has broken above that monthly downtrend line. We should know for sure by tomorrow.
0 · Reply
JohnnyP5
JohnnyP5 Dec. 3 at 9:52 AM
$TAOX hopefully see a bit of a bounce today.
0 · Reply
bigkahunatrader
bigkahunatrader Dec. 3 at 6:54 AM
$TAOX Tao Synergies, Inc. TY-2 Cycle Trade...Stock Rating B-87 https://youtu.be/V3Nwu5ieydw
0 · Reply
EndGame1
EndGame1 Dec. 2 at 2:42 PM
$TAOX BTC has bottomed...maybe? Long live TAO.
0 · Reply
EndGame1
EndGame1 Dec. 2 at 3:20 AM
$TAOX Vanguard to save crypto and the market. "Vanguard Will Now Allow Crypto ETFs on Its Platform."
0 · Reply
EndGame1
EndGame1 Dec. 2 at 12:13 AM
$TAOX As of the close I'm still positive $103.00 on a $63,736.00 investment here.
0 · Reply
Arcides
Arcides Dec. 1 at 5:30 PM
$TAOX crypto related are shit right now.
0 · Reply
TaoistTrader
TaoistTrader Dec. 1 at 5:16 PM
$TAOX shake the tree before the run up ? 🤔
0 · Reply
EndGame1
EndGame1 Dec. 1 at 3:18 PM
$TAOX Buy of a lifetime or not? All depends on where $BTC bottoms. I'll hold either way.
0 · Reply